IV antibiotic study for children with complex urinary tract infections
Part of Infections, Kidney & urinary clinical trials.
This study tests a new IV antibiotic combination (cefepime-enmetazobactam) for children with complicated urinary tract infections or kidney infections. The goal is to see how well it works and if it is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be under 18 years old (including newborns at least 32 weeks gestational age).
- Your child must have a complicated urinary tract infection or kidney infection that needs IV antibiotics in the hospital.
- Your child must have signs of infection, such as fever, pain, or burning when urinating, and a urine test showing infection.
- Your child must not have taken antibiotics in the last 24 hours unless the previous antibiotic didn't work.
- Your child must not have severe allergies to penicillin or similar antibiotics.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether one dose of intravenous (IV) antibiotics is as effective as the usual multiple-dose course for children with complicated urinary tract infections (UTIs) who need IV treatment in the emergency department. It aims to reduce hospital stays and the need for repeated IV lines.
This trial tests a combination of two antibiotics (cefepime and enmetazobactam) to treat complicated urinary tract infections that have spread to the blood. It aims to see if this new combination works better than other antibiotics and is safe for patients.
This trial tests a new antibiotic combo (ertapenem-zidebactam) against an existing one (ceftazidime-avibactam) for serious urinary tract or kidney infections in hospitalized patients. It aims to see if the new drug is as effective and safe.
This trial tests whether the antibiotic cefotetan works as well as current standard treatments for E. coli bloodstream infections that start in the urinary tract. If you qualify, you may receive either cefotetan or the usual antibiotic therapy.
This Phase 2 trial tests LBP-EC01 to treat a bladder infection (UTI) caused by drug-resistant E. coli. It may help by targeting the specific bacteria that make UTIs harder to cure with common antibiotics.
This trial tests a single dose of an investigational antibiotic called gepotidacin in hospitalized children with bacterial infections who already have an IV line. The medicine is given as a powder mixed with food, and the study aims to see how well it is absorbed and tolerated.
Hear when a new Complicated Urinary Tract Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.